SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community discusses recent news and potential impacts from political decisions. Community members are focused on trade negotiations and tariff implications, as well as commentary around political figures and events. Broader discussions include market dynamics and potential financial strategies related to the stock.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

The crypto asset $BALLIN is gaining attention, particularly within the Phantom Wallet community, with many highlighting its potential for significant gains. Community members are encouraged to buy and hold, emphasizing the opportunity for early entry and substantial profits. The focus is on strong upward momentum and the potential for a breakout.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies ($LUMN) is trending amid discussions about its role in AI infrastructure, particularly following a $200M deal with Palantir ($PLTR) to boost enterprise AI. Community members highlight Lumen's fiber optic network and partnerships with hyperscalers as key assets for AI data connectivity. Some are speculating on future earnings and potential government stakes in the company.

Mkango Resources Ltd.

Mkango Resources is trending amid discussions about rare earth elements and critical mineral demand. Community members are pointing to supply chain developments and broader interest in the sector as potential catalysts. Some traders are attributing recent price action to warrant exercises while others see it as a temporary cooling off period before another potential move.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing increased volatility, with community members actively discussing potential breakouts and resistance levels. Recent market activity and whale movements are sparking conversations about whether ETH can sustain its gains. Broader narratives around tokenization and potential ETF staking approvals are also influencing sentiment, adding to the current price swings.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to upcoming presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting in November, where the company will share insights from its enLIGHTEN Discovery Platform and additional data from the CAN-2409 program. The community is also discussing the company's prioritization of prostate cancer and NSCLC, as well as potential partnerships for its pancreatic cancer treatment. Bullish investors are optimistic about the long-term potential, citing the large market opportunities and the company's experienced leadership team.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending due to recent earnings, mixed reactions to the CEO's conference call, and fluctuating gold prices, leading to debate on its short-term performance. The community is discussing whether NEM's stock drop is a buying opportunity or a sign of deeper issues, with some citing its strong fundamentals and others pointing to concerns about cash flow and CEO communication. Despite mixed sentiment, Newmont's long-term outlook remains positive, driven by solid earnings growth expectations and a potentially undervalued stock price in the precious metals mining sector.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as the community discusses its strong pharmaceutical pipeline and potential acquisitions, particularly after positive trial results and an increased focus on neuroscience. Bullish sentiment is fueled by rising sales of Skyrizi and Rinvoq, offsetting Humira's decline, alongside speculation about potential M&A activity in the sector. The community is closely watching upcoming earnings and price target adjustments by analysts.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?

The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Anika (ANIK) Upgraded to Buy: Here's What You Should Know

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

Shares of Anika Therapeutics ($ANIK), which provides early intervention for orthopedic care, slipped 3.39% on Friday, a day after the company’s results fell short of Wall Street estimates even as the retail sentiment stayed cautious.Anika has beaten earnings estimates three times in the last four quarters. For the third quarter, the company posted earnings per share (EPS) of - $0.25, missing the consensus estimate of $0.09. Its net loss widened to $29.9 million from $6.6 million in the year-ago period. The company’s reported revenues of $38.75 million were 7.91% below consensus estimates.It also updated its guidance on its 2024 adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda, expecting it to fall between $16 and $18 million.Barrington analyst Michael Petusky has cut the firm’s price target to $25 from $37&nbsp; while maintaining an “Outperform” rating on its stock following the results, The Fly.com <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=ANIK">reported,</a> citing “weakening OA pain volumes and softer pricing” that collectively drove its more pessimistic outlook.Petusky’s price target is based on the company’s FY25 adjusted EBITDA estimate plus $50M of value it adds for the company’s “two potential needle-mover products” – Cingal and Hyalofast – that have completed “pivotal trials” but are yet to receive regulatory approval, the report added.Retail sentiment has remained ‘neutral’ on the stock even as the message volumes soared into the ‘extremely high’ zone.<figure class="image"><img style="aspect-ratio:1304/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_02_at_1_34_53_AM_d6d50fb11b.png" alt="Screenshot 2024-11-02 at 1.34.53 AM.png" width="1304" height="306"><figcaption>ANIK sentiment meter and message volumes on Nov 1 as of 4:36 pm ET</figcaption></figure>Anika also announced the sale of its Arthrosurface business for $10 million, and said it was actively pursuing the sale of another division, Parcus Medical, as part of its efforts to refocus on its strategy. The sale will “optimize” the company's capital allocation and redouble efforts on its profitable core hyaluronic acid (HA) technology and Regenerative Solutions portfolios.Some users were optimistic about its long-term prospects despite shares being down 27% year-to-date.<stembedurl>https://stocktwits.com/Aigner_Andreas/message/582406016</stembedurl>For updates and corrections, email newsroom@stocktwits.com

he company’s reported revenues of $38.75 million were 7.91% below consensus estimates. | Image source: Pixabay

Retail Investors Remain Cautious After Anika’s Q3 Earnings Misses Estimates

Barrington analyst Michael Petusky has cut the firm’s price target to $25 from $37 

Equity

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics PR Newswire WEST BRIDGEWATER, Mass...

Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights

Latest Ratings for ANIK
 DateFirmActionFromTo Mar 2022Stephens & Co.DowngradesOverweightEqual-Weight Nov 2021Stephens & Co.Initiates Coverage OnOverweight Jul 2021UBSInitiates Coverage OnNeutral...

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

ANIK
Anika Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ANIK News

ANIKAnika Therapeutics Inc.